Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
Leukemia (2016) 30, 2405-2409; doi:10.1038/leu.2016.228 Lenalidomide (LEN) treatment leads to red blood cell transfusion independence in approximately two-thirds of anemic myelodysplastic syndrome (MDS) patients with del(5q). 1 Some patients also experience cytogenetic remissions, whereas in others the del(5q) abnormality persists. 1 Furthermore, responses also occur in~25% of MDS patients without del(5q). 2 This suggests that, in addition to del(5q), other molecular lesions may also be associated with sensitivity to LEN. To date, apart from del(5q), no reliable predictive factors for LEN responsiveness have been reported, but clinically patients with early MDS, normal/low-risk cytogenetics, or anemia with preserved platelet and neutrophil counts appear to be better LEN candidates than those with more advanced disease, complex cytogenetics and cytopenias. 3 On a molecular level, although initial attempts to prospectively identify responders based on gene expression patterns suggested response-specific signatures, 4 they have not been translated into an actionable test, and have not been validated in non-del(5q) cases. 5 Recently, the mechanism of action of LEN has been attributed to induction of ubiquitination and enhanced degradation of casein kinase 1A1 (CK1α) by the E3 ubiquitin ligase cereblon. 6 To identify new biomarkers of sensitivity to LEN, using next-generation sequencing, we determined whether recurrent mutations can help predict response or resistance to LEN in patients with myeloid malignancies.
We have collected a unique cohort of patients with and without del(5q) who underwent routine therapy with LEN and have Accepted article preview online 18 August 2016; advance online publication, 23 September 2016 adequate clinical and molecular annotation. Informed consent in accordance with Institutional Review Board-approved protocols of participating institutions was obtained for sample collection from 137 patients (Supplementary Tables 1 and 2) , of whom 108 patients were treated with LEN alone (Table 1) and 29 patients received LEN in combination with another agent. WHO classification (2008), IPSS-R and International Working Group Criteria (2006) were used to define clinical characters. Patients treated with at least two cycles of LEN were analyzed. Technical details regarding single nucleotide polymorphism array have been previously described. 7 Multi-amplicon deep sequencing (TruSeq; Illumina, San Diego, CA, USA) was performed for 45 genes most commonly mutated in MDS ( Supplementary Table 3 ). Algorithms for identification of somatic lesions, exclusions of germ line alterations and removal of technical artifacts were previously reported. 8 Logistic regression, Fisher's exact test and the Mann-Whitney U test were used to identify covariates that correlated significantly (two-sided α of 0.05) with response. Multivariate logistic regression models were identified using backward stepwise selection. We identified 108 cases of myeloid neoplasms (MDS, MDS/ myeloproliferative neoplasms (MPN), or MPN) treated with LEN alone. The median duration of treatment was 5 months (range 2-66). Patients were subgrouped into LEN-responder (n = 55) and LEN-refractory (n = 53) cases (Table 1) . Initially, we combined isolated del(5q) (n = 29), del(5q) with additional cytogenetic abnormalities (n = 17) and non-del(5q) (n = 62) cases. Patient IPSS-R risks were grouped as either very low/low/intermediate (92%) or high/very high (8%). Hematologic improvement, partial response (PR), complete response (CR, marrow CR) or any response (unknown detail) was achieved in 12 (22%), 5 (9%), 19 (34.5%) and 19 (34.5%) of the cases, respectively. In those treated with LEN alone the del(5q) group overall response rate (ORR) was 65% (30 responded), whereas in non-del(5q) patients it was 40% (23 responded) ( Supplementary Tables 4 and 5 ). The relatively favorable response rate in the non-del(5q) cohort treated in these series may reflect the rational selection of likely responders based on empiric criteria, though this ORR was similar to that of previous studies. 1, 2 Analyses of clinical parameters, including age, absolute neutrophil counts, blast counts, hemoglobin and IPSS-R scores, indicated that responders had significantly higher platelets, were more likely to be female, were treated for a longer period of time, had lower IPSS-R scores and were less likely to have excess blasts ( Table 1) . The resultant multivariate model of ORR included as covariates platelets and the presence of isolated del(5q); using only the del(5q) cohort, the covariates were MDS type and the positivity for PRC2 complex lesions. Within isolated low-risk MDS cohort, del(5q) remained the only predictive covariate ( Supplementary Table 6 ). When stratifying based on del(5q) status, in the del(5q) cohort, responders were less likely to have refractory anemia with excess blasts, and more likely to have lower IPSS-R scores, higher platelets and a longer treatment period ( Supplementary Table 4 ); in the non-del(5q) cohort, higher platelets and longer treatment duration also predicted response ( Supplementary Table 5 ). When MDS patients were subgrouped according to the status of disease (low risk: MDS with IPSS-R very low/low/intermediate, MDS/MPN-u and CMML-1 vs high risk: MDS with IPSS-R (high/very high)), all responses occurred in the low-risk category, and responders were likely to have del(5q), isolated del (5q), 5q-MDS, higher platelets and longer treatment duration, whereas nonresponders had normal karyotype and CMML-1 (Supplementary Table 7 and Supplementary Figure 1 ). Within cohorts defined by morphological features, such as the presence of ring sideroblasts, and uni-vs multi-lineage dysplasia, the responders were not enriched nor a mutational pattern emerged that would predict response (data not shown).
We next examined genomic differences between LEN responders and refractory patients. Cytogenetics, namely complex aberrations, − 7/del(7q), +8, − 20/del(20q) and − Y, were not associated with response to LEN, but, as expected, del(5q) and isolated del(5q) were significantly associated with response: odds ratios (ORs) of response in all patients were 2.1 (1, 4.7), P = 0.04 and 4.2 (1.5, 13.6), P = 0.003 for del(5q) and isolated del(5q), respectively (Figure 1a ), and 2.7 (1.2, 6.7), P = 0.02 and 5.5 (2, 19) , Po0.001 when using monotherapy (Figure 1b and Supplementary Figure 2 ). Both del(5q) long (includes the commonly retained region, CRR) and short (excludes CRR) showed equal sensitivity to LEN (Figures 1a and b) .
We also applied targeted sequencing ( Supplementary Table 3 ) or (in selected cases) whole-exome sequencing to identify mutations (Supplementary Table 8 ) that constitute LEN resistance factors. Overall, focusing on OR, the number of mutational events per patient was not associated with responses (responder vs nonresponder; OR 1.8 vs 2.3, P = 0.35). Subsequently, we analyzed the types of alterations in all cases treated with LEN alone or with combination therapy. U2AF1 (OR o 0.5) was overrepresented in refractory cases, whereas rates for DEAD box RNA helicase combined (DDX41, DDX54 and DHX29), OR = 3.4 (1, 15.1) were significantly higher in responders (Figure 1a ). Since the total cohort included patients with combination therapies, to avoid confounding factors, we focused our analyses on cases treated with LEN alone. U2AF1 mutations were significantly associated with failure to respond to LEN (0% vs 11%, P = 0.01; Figure 1b ). When reverse analysis was performed for all the genes tested for mutations and deletions, U2AF1 mutations were also less common among responders (0% response among U2AF1 MT vs 54% among U2AF1 WT cases; OR o0.8; Supplementary Figure 2 ) and 5/6 cases were found in the non-del(5q) cohort (0% response among U2AF1 MT vs 44% among U2AF1 WT cases; OR o1.5; Figure 1c ). Previously, MDS patients with U2AF1 mutations have been associated with a higher progression rate and poor prognosis. 9 Similarly, TP53 mutations predict response failures, suggesting that del(5q) MDS with TP53 MT might be a clinically important molecular configuration. 10 However, two cases with TP53 mutations were found in the context of del(5q) with complex karyotype (Figures 1b and c) and both, who received LEN alone, were refractory. In contrast, 3/4 (75%) TP53 mutant or deletion cases who received LEN+Azacitidine combination showed clinical improvement (Figure 1a ). When we explored additional LEN sensitivity factors in our del(5q) cohort, no individual significant somatic mutations were found (Figure 1c) , though PRC2 complex genes (EZH2, SUZ12 and DNMT3A) were significantly associated with poor risk by multivariate analysis, and were consistent with the known unfavorable prognosis of EZH2 mutations. 11 EZH2 and SUZ12 are components of the PRC2/EED-EZH2 complex; mutations reduce PRC2 histone methyltransferase activity. 12 Previously, CSNK1A1 mutation has been shown to convey a poor prognosis in patients with the del(5q) abnormality, 13 but in our cohort, with a limited number of mutant cases, no impact on response to LEN was noted (OR o34). Recently, DDX41 mutations have been reported to be associated with LEN sensitivity. 14 Among seven patients with heterozygous DDX41 mutations or deletions who received LEN alone, the response rate was 57%, OR = 1.3 (0.2, 9.4) ( Supplementary Figure 2) and all DDX41 mutants without deletions (n = 3) were responders (Figure 1b ). In the non-del(5q) cohort, DEAD box RNA helicase (DDX41, DDX54 and DHX29) mutations/deletions were significantly more common in responders (P = 0.02).
Grouping clone sizes to identify dominant-likely ancestral events (SF3B1, TET2, JAK2, GPR98, PRPF8, STAG2, DNMT3A and ZRSR2) did not yield significant results ( Supplementary Table 9 and Supplementary Figure 3) . In a recent study of patients treated with LEN and erythropoietin, combined predictors that do not include mutation status were described, and analysis of clonal architecture showed effects on subclonal distribution, whereas loss of responsiveness was associated with the re-expansion of the dominant subclone. 15 In conclusion, in addition to the presence of del(5q), gender, platelet counts, treatment period, MDS type and IPSS-R, the U2AF1 mutation in the entire cohort, mutations in TP53 in the del(5q) cohort and DEAD box RNA helicases in the non-del(5q) cohort grouped with responses to LEN.
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Dissection of CD20 regulation in lymphoma using RNAi
Leukemia (2016) 30, 2409-2412; doi:10.1038/leu.2016.230 CD20, encoded by MS4A1, is a cell surface glycoprotein involved in calcium signaling, 1 expressed on normal and malignant B cells. Antibodies targeting CD20 (for example, rituximab) are used for the treatment of B-cell lymphoma, and mediate antitumor response by complement-dependent cytotoxicity (CDC), antibodydependent cellular cytotoxicity and direct induction of apoptosis. 2 Resistance to anti-CD20 antibodies remains a clinical challenge. Transcription factors like SPI1/PU.1, 3 Oct2 (ref. 4) and Pax5 (ref. 5) have been described in MS4A1 regulation, however, other factors (e.g., epigenetic changes, somatic mutations, noncoding RNA) could also affect the CD20 expression levels.
To identify genes regulating CD20 surface expression, we performed a genome-wide RNAi screen using a library of barcoded small hairpin RNAs (shRNAs) delivered by lentiviral vectors. In total, the library targeted 15 377 messenger RNAs (mRNAs) with 5-6 shRNAs per transcript in three separate modules. We chose the Raji cell line (Burkitt's lymphoma) characterized by intermediate CD20 levels (Supplementary Figure S1 ). After 6 days, infected cells were fluorescenceactivated cell sorting (FACS)-sorted according to CD20 expression generating CD20 low and CD20 high populations (Figure 1a , Supplementary Figure S2 ), and barcodes were sequenced ( Supplementary Table S1 ). shRNA barcode counts were highly reproducible between replicates (Pearson correlation 0.91-0.96-for unsorted, 0.71-0.86-for sorted populations; Supplementary Figure S3 ). After filtering based on expression, candidate genes were identified using the weighted z-score method (Supplementary Materials and Methods, Supplementary  Tables S2-S4 ). The positive control MS4A1 was ranked first in the CD20 low population (Figures 1b and c) . We identified two transcription factors that have previously been described as MS4A1 regulators: PAX5 (rank 11) 5 and SPI1 (rank 16). 3 To select novel candidates, we applied a weighted z-score threshold of 3.5, which yielded 37 candidate CD20 repressors and 51 potential activators across the three modules (Figure 1b ; Supplementary Figures S3-S5) . We chose 17 candidate regulators and 10 control genes for validation. Although 16 out of 20 tested shRNAs targeting controls did not change CD20 levels by 415%, we observed a consistent decrease or increase of CD20 expression for 16 of 17 candidates, with at least 2 shRNAs (Figure 1c, Supplementary Figure S6 ). These data support the performance of the RNAi pipeline.
CREM (cAMP-responsive element modulator) was identified as a top candidate for CD20 suppression (Figures 1b and c) . Three nonoverlapping shRNAs targeting CREM efficiently decreased CREM mRNA and protein levels, and resulted in upregulation of surface CD20 levels ( Supplementary Figures S6 and S7 ) across 6 out of 7 lymphoma cell lines (Supplementary Figure S8) . To assess the specificity of CREM knockdown, we examined additional B-cell surface receptors (CD81, CD79b, CD19, CD22, CD38 and CD72). Only the level of CD72 expression also increased after CREM knockdown, albeit to a lower extent (Supplementary Figure S7c) suggesting a specific role of CREM for CD20 regulation. As the promoter region of CD20 contains three half-cAMP response elements sites, which were previously reported as binding motives for CREM in primary T cells 6 (Supplementary Figure S9a) , we investigated CREM-binding capacity to the CD20 promoter. We used two different CREM antibodies and SPI1 antibodies as a positive control. 3 Our ChIP-PCR showed that CREM binds the MS4A1 promoter region (Supplementary Figure S9b) ; however, we did not observe an increase in promoter activity upon CREM knockdown (Supplementary Figure S9c) . Taken together, our work associates the transcriptional repressor CREM with the regulation of MS4A1.
We identified CHD4 (chromodomain helicase DNA-binding protein 4) and MBD2 (methyl-CpG-binding domain protein 2) as CD20 activators (Figures 1b and c, Supplementary Figure S6 ). CHD4 and MBD2 are members of the nucleosome remodeling deacetylase (NuRD) complex, which controls DNA accessibility to activate or repress gene transcription. 7 shRNAs for MBD2 and CHD4 resulted in downregulation of both targets and CD20 mRNA in Raji cells (Supplementary Figure S10) , and downregulation of surface CD20 in additional cell lines (GRANTA-519 and YAKOBO, Supplementary Figure S8 ). To confirm these findings, we used CRISPR/Cas9, and designed single guide RNA (sgRNA) targeting Accepted article preview online 18 August 2016; advance online publication, 20 September 2016
